Blastomycosis
(Blastomyces dermatitidis)
Material: | Antibody demonstration: 1 ml serum PCR: EDTA-blood, sputum, BAL, puncture and biopsy specimens Pathogen detection: BAL, sputum, puncture and biopsy specimens Cultures only after prior telephone discussion. |
Methods: |
Ligandenassays → Immunfluoreszenzassay (IFA) Amplifikationsverfahren → Real-time-PCR | Criteria for evaluation | Titer: < 1:10 PCR: negative |
Indication | Suspicion of imported systemic mycosis |
Please note | Blastomyces dermatitidis is the pathogen of the Northern American blastomycosis. Incidence: Central- and South Eastern US, Central America, Canada, Africa, but also in India, Israel and Saudi Arabia. Communication via spore-containing dusts. Incubation time from 3 weeks to several months. Initially, pulmonary infestation with high fever, cough and lobular infiltrates, in 50 % of patients asymptomatic course, later focal infestation of skin, lungs, bones and liver as chronic-granulomatous infection. According to the technical rules for biological agents (TRBA) no. 460, this is a pathogen of risk group 3. This means, that there is a high level of threat for laboratory personnel when bacterial cultures are grown (pathogen detection). In case of such a request, prior telephone consultation is required. For further information, please refer to www.rki.de |
External services | ja Robert Koch-Institut, Standort Berlin Konsiliarlabor Mykologie |
More Results for the letter B
- Blood group serology (BG)
- Blood in stool, immunological (IFOB)
- iFOBT
- Bordetella pertussis/parapertussis (PERT)
- Whooping cough
- Borrelia vincenti (BORR01)
- Spirochaeta vincenti
- Borreliosis (BOR)
- Borrelia burgdorferi and other species
- Botulism (CLOS)
- Clostridium botulinum
- BRCA1 and BRCA2 mutation analysis (BRCA1)
- Brillant cresyl blue staining (BRIL)
- Brivaracetam (BRIVA)
- Bromazepam (BROMA)
- Bromine in serum (BRO)
- as Bromide
- Bronchial lavage / Bronchoalveolar lavage (BAL)
- Brucellosis (BRUC)
- Buprenorphine (BUPR)